CYP2C9 gene and susceptibility to major depressive disorder

A. Llerena, R. Berecz, P. Dorado, A. P. González, E. M. Peñas-Lledó, A. De la Rubia

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disorders, and CYP2C9 enzyme activity has been shown to be modulated by serotonin in vitro. The present study was aimed at analysing the frequency of CYP2C9 alleles (*1, *2, *3) among patients suffering from major depressive disorder. In all, 70 such suffering psychiatric outpatients were studied. The CYP2C9 genotypes were determined by allele-specific PCR. The CYP2C9*3 allele frequency was higher (P

Original languageEnglish
Pages (from-to)300-302
Number of pages3
JournalPharmacogenomics Journal
Volume3
Issue number5
DOIs
Publication statusPublished - 2003

Fingerprint

Major Depressive Disorder
Gene Frequency
Genes
Mood Disorders
Psychological Stress
Synaptic Transmission
Psychiatry
Serotonin
Outpatients
Alleles
Genotype
Polymerase Chain Reaction
Cytochrome P-450 CYP2C9
Enzymes

Keywords

  • CYP2C9 gene
  • Depression
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Llerena, A., Berecz, R., Dorado, P., González, A. P., Peñas-Lledó, E. M., & De la Rubia, A. (2003). CYP2C9 gene and susceptibility to major depressive disorder. Pharmacogenomics Journal, 3(5), 300-302. https://doi.org/10.1038/sj.tpj.6500197

CYP2C9 gene and susceptibility to major depressive disorder. / Llerena, A.; Berecz, R.; Dorado, P.; González, A. P.; Peñas-Lledó, E. M.; De la Rubia, A.

In: Pharmacogenomics Journal, Vol. 3, No. 5, 2003, p. 300-302.

Research output: Contribution to journalArticle

Llerena, A, Berecz, R, Dorado, P, González, AP, Peñas-Lledó, EM & De la Rubia, A 2003, 'CYP2C9 gene and susceptibility to major depressive disorder', Pharmacogenomics Journal, vol. 3, no. 5, pp. 300-302. https://doi.org/10.1038/sj.tpj.6500197
Llerena A, Berecz R, Dorado P, González AP, Peñas-Lledó EM, De la Rubia A. CYP2C9 gene and susceptibility to major depressive disorder. Pharmacogenomics Journal. 2003;3(5):300-302. https://doi.org/10.1038/sj.tpj.6500197
Llerena, A. ; Berecz, R. ; Dorado, P. ; González, A. P. ; Peñas-Lledó, E. M. ; De la Rubia, A. / CYP2C9 gene and susceptibility to major depressive disorder. In: Pharmacogenomics Journal. 2003 ; Vol. 3, No. 5. pp. 300-302.
@article{57a4c49a7b1049d18bf3b73df7176e8b,
title = "CYP2C9 gene and susceptibility to major depressive disorder",
abstract = "Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disorders, and CYP2C9 enzyme activity has been shown to be modulated by serotonin in vitro. The present study was aimed at analysing the frequency of CYP2C9 alleles (*1, *2, *3) among patients suffering from major depressive disorder. In all, 70 such suffering psychiatric outpatients were studied. The CYP2C9 genotypes were determined by allele-specific PCR. The CYP2C9*3 allele frequency was higher (P",
keywords = "CYP2C9 gene, Depression, Schizophrenia",
author = "A. Llerena and R. Berecz and P. Dorado and Gonz{\'a}lez, {A. P.} and Pe{\~n}as-Lled{\'o}, {E. M.} and {De la Rubia}, A.",
year = "2003",
doi = "10.1038/sj.tpj.6500197",
language = "English",
volume = "3",
pages = "300--302",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - CYP2C9 gene and susceptibility to major depressive disorder

AU - Llerena, A.

AU - Berecz, R.

AU - Dorado, P.

AU - González, A. P.

AU - Peñas-Lledó, E. M.

AU - De la Rubia, A.

PY - 2003

Y1 - 2003

N2 - Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disorders, and CYP2C9 enzyme activity has been shown to be modulated by serotonin in vitro. The present study was aimed at analysing the frequency of CYP2C9 alleles (*1, *2, *3) among patients suffering from major depressive disorder. In all, 70 such suffering psychiatric outpatients were studied. The CYP2C9 genotypes were determined by allele-specific PCR. The CYP2C9*3 allele frequency was higher (P

AB - Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disorders, and CYP2C9 enzyme activity has been shown to be modulated by serotonin in vitro. The present study was aimed at analysing the frequency of CYP2C9 alleles (*1, *2, *3) among patients suffering from major depressive disorder. In all, 70 such suffering psychiatric outpatients were studied. The CYP2C9 genotypes were determined by allele-specific PCR. The CYP2C9*3 allele frequency was higher (P

KW - CYP2C9 gene

KW - Depression

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0242575123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242575123&partnerID=8YFLogxK

U2 - 10.1038/sj.tpj.6500197

DO - 10.1038/sj.tpj.6500197

M3 - Article

C2 - 14583800

AN - SCOPUS:0242575123

VL - 3

SP - 300

EP - 302

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 5

ER -